EICHOR
● Active Not Recruiting
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Condition: Cholangiocarcinoma · Sponsor: TransThera Sciences (Nanjing), Inc.
About this study
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (87)
| UCLA Medical Center | Santa Monica, California, United States | — |
| Stanford Cancer Center | Stanford, California, United States | — |
| The University of Kansas Cancer Center | Westwood, Los Angeles, California, United States | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | — |
| The University of Chicago Hospitals | Chicago, Illinois, United States | — |
| UMass Memorial Medical Center | Worcester, Massachusetts, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Henry Ford | Detroit, Michigan, United States | — |
| University of Minnesota- Masonic Cancer Center, M Health Fairview | Minneapolis, Minnesota, United States | — |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | — |
| Messino Cancer Centers | Asheville, North Carolina, United States | — |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | — |
+ 75 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05948475